小児糖尿病管理市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、エンドユーザー別、地域別、競合別、2020-2030年

小児糖尿病管理の世界市場規模は2024年に56億6,000万米ドル、2030年には100億1,000万米ドルに達すると予測、CAGRは9.94%。

世界小児糖尿病管理市場は、小児および青少年における糖尿病有病率の増加により、革新的な管理ソリューションの需要を牽引し、大きな成長を遂げています。小児糖尿病、特に1型糖尿病は、糖尿病性ケトアシドーシスのような急性合併症や成長・発達への長期的影響を防ぐために、継続的なモニタリングと正確なインスリン投与が必要です。持続グルコースモニタリング（CGM）システム、自動インスリン投与（AID）装置、スマートインスリンポンプなどの技術の進歩により、より正確で便利な血糖値管理が可能となっています。病院、診療所、在宅ケアの現場では、これらのソリューションをケアプロトコールに組み込むケースが増えており、患者のアドヒアランスと臨床転帰を改善しています。早期介入と効果的な糖尿病管理の重要性に関する保護者、介護者、医療提供者の意識の高まりも市場拡大に寄与しています。

市場を牽引している主な要因はいくつかあります。小児糖尿病の世界的な増加により、継続的なモニタリングと個別ケアを必要とする患者数が増加しています。先進的なインスリン送達システムとCGMデバイスの採用により、血糖コントロールが向上し、急性の緊急事態や長期的な合併症のリスクが低減します。ヘルスケアプロバイダーは、患者中心のアプローチを重視し、個々の子供のニーズに合わせて治療計画を立て、デジタルツールを活用してグルコースレベルを追跡し、インスリン投与量を調整し、遠隔監視を行っています。予測分析やデータ主導の意思決定など、医療技術の絶え間ない進歩により、臨床医はリスクの高いエピソードを予測し、積極的に介入することができます。医療機器企業による研究開発への投資の増加により、小児糖尿病管理ソリューションの技術革新が加速しており、患者と医療従事者の双方に、より安全で効率的な、使いやすい選択肢が提供されています。

市場の新たな動向としては、CGMデータとインスリン送達システムを統合してリアルタイムで調整するコネクテッド・ヘルスケア・テクノロジーの統合が挙げられます。遠隔医療プラットフォームは、遠隔モニタリングやコンサルテーションをサポートし、家族が自宅で小児糖尿病を管理しながら通院回数を減らすのに役立っています。アルゴリズム主導のインスリン投与を含む個別化治療アプローチは、治療の精度と有効性を高めています。市場は力強い成長が見込まれるもの、地域によっては認知度が限定的であること、先進的な機器の価格が高く利用しにくいこと、これらの技術を効果的に使用するには医療従事者に専門的なトレーニングが必要であることなどの課題に直面しています。規制上のハードルや、新しい機器の長期的な安全性と有効性に関する懸念は、普及を遅らせる可能性があります。教育、政策支援、技術革新を通じてこれらの課題に対処することは、世界小児糖尿病管理市場の成長を持続させ、糖尿病とともに生きる子どもたちにより良い結果をもたらすために不可欠です。

主な市場促進要因

小児糖尿病の有病率の上昇

主な市場課題

先進デバイスと治療法の高コスト

主要市場動向

デジタルヘルスソリューションの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の小児糖尿病管理市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（血糖値モニター（BGM）、持続血糖モニター（CGM）、インスリンポンプ、インスリンペン、インスリンシリンジ）
  • テクノロジー別（接続デバイス、非接続デバイス）
  • エンドユーザー別（病院、在宅ケア、小児科クリニック）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の小児糖尿病管理市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の小児糖尿病管理市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の小児糖尿病管理市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の小児糖尿病管理市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの小児糖尿病管理市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Medtronic plc
• DexCom, Inc.
• Abbott Laboratories
• Tandem Diabetes Care, Inc.
• Insulet Corporation
• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Roche Diabetes Care, Inc.
• Ascensia Diabetes Care Holdings AG

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Pediatric Diabetes Management Market was valued at USD 5.66 Billion in 2024 and is expected to reach USD 10.01 Billion by 2030 with a CAGR of 9.94%. The Global Pediatric Diabetes Management Market is witnessing significant growth due to the increasing prevalence of diabetes among children and adolescents, which is driving demand for innovative management solutions. Pediatric diabetes, particularly type 1 diabetes, requires continuous monitoring and precise insulin administration to prevent acute complications such as diabetic ketoacidosis and long-term effects on growth and development. Advances in technology, including continuous glucose monitoring (CGM) systems, automated insulin delivery (AID) devices, and smart insulin pumps, are enabling more precise and convenient management of blood glucose levels. Hospitals, clinics, and homecare settings are increasingly integrating these solutions into care protocols, improving patient adherence and clinical outcomes. Growing awareness among parents, caregivers, and healthcare providers regarding the importance of early intervention and effective diabetes management is also contributing to the market's expansion.

The market is being driven by several key factors. Rising incidence of pediatric diabetes globally is creating a larger patient pool that requires continuous monitoring and personalized care. Adoption of advanced insulin delivery systems and CGM devices enables better glycemic control, reducing the risk of acute emergencies and long-term complications. Healthcare providers are emphasizing patient-centric approaches, tailoring treatment plans to individual children's needs, and leveraging digital tools to track glucose levels, adjust insulin dosing, and provide remote monitoring. Continuous advancements in medical technologies, including predictive analytics and data-driven decision-making, allow clinicians to anticipate high-risk episodes and intervene proactively. Increasing investments in research and development by medical device companies are accelerating innovation in pediatric diabetes management solutions, offering safer, more efficient, and user-friendly options for both patients and healthcare professionals.

Emerging trends in the market include the integration of connected healthcare technologies that combine CGM data with insulin delivery systems for real-time adjustments. Telemedicine platforms are supporting remote monitoring and consultation, helping families manage pediatric diabetes at home while reducing hospital visits. Personalized treatment approaches, including algorithm-driven insulin dosing, are enhancing the precision and effectiveness of care. Despite strong growth prospects, the market faces challenges such as limited awareness in certain regions, high costs of advanced devices that may restrict accessibility, and the need for specialized training of healthcare professionals to use these technologies effectively. Regulatory hurdles and concerns regarding long-term safety and efficacy of new devices may slow adoption. Addressing these challenges through education, policy support, and technological innovation is essential to sustaining growth in the Global Pediatric Diabetes Management Market, ensuring better outcomes for children living with diabetes.

Key Market Drivers

Rising Prevalence of Pediatric Diabetes

A major driver of the Global Pediatric Diabetes Management Market is the rising prevalence of pediatric diabetes, which has been increasing steadily due to a combination of genetic, environmental, and lifestyle factors. Type 1 diabetes remains the most common form among children and adolescents, requiring lifelong insulin therapy and continuous monitoring to prevent acute complications such as diabetic ketoacidosis (DKA) and long-term health issues affecting growth, cardiovascular health, and kidney function. At the same time, the incidence of type 2 diabetes is rising among younger populations, driven by childhood obesity, sedentary lifestyles, and poor dietary habits, creating an additional patient pool that requires regular monitoring, insulin therapy, and lifestyle interventions. According to the International Diabetes Federation, around 1.52 million people aged 20 years had diabetes in 2022, highlighting the significant burden of the disease and underscoring the urgent need for effective management solutions. This dual burden of type 1 and type 2 diabetes is intensifying demand for reliable pediatric diabetes management products and services.

Healthcare providers are recognizing the critical need for early diagnosis and intervention to manage glycemic levels efficiently and prevent complications. Continuous glucose monitoring (CGM) systems, automated insulin delivery (AID) devices, and smart insulin pumps are increasingly being adopted to provide real-time insights, personalized insulin dosing, and predictive alerts for hypoglycemic or hyperglycemic events. Rising prevalence is also driving investment in caregiver education programs and pediatric-specific treatment protocols, ensuring adherence to therapy and effective disease management. The increasing number of children diagnosed with diabetes is prompting healthcare systems, hospitals, and clinics to expand infrastructure, implement advanced monitoring solutions, and integrate digital health tools to improve patient outcomes. This growing patient base, combined with technological advancements and awareness initiatives, is a key factor propelling the expansion of the pediatric diabetes management market globally, reflecting the urgent need for specialized and accessible care solutions for young patients living with diabetes.

Key Market Challenges

High Cost of Advanced Devices and Therapies

A significant challenge facing the Global Pediatric Diabetes Management Market is the high cost of advanced devices and therapies, which limits accessibility for many families, particularly in low- and middle-income regions. Advanced technologies such as continuous glucose monitors (CGM), automated insulin delivery (AID) systems, and smart insulin pumps offer precision, convenience, and improved glycemic control, but their high purchase prices often ranging from USD 1,000-6,000 for pumps and USD 2,000-5,000 annually for CGM sensors create substantial financial barriers. Many families are unable to afford these technologies without adequate insurance coverage or government subsidies, resulting in disparities in pediatric diabetes care. The cost factor affects device adoption and long-term treatment adherence, as children relying on traditional finger-prick glucose meters and manual insulin injections face less precise monitoring, increasing the risk of acute complications such as diabetic ketoacidosis (DKA) and long-term health consequences.

High costs also constrain healthcare providers in standardizing advanced management solutions, especially in emerging markets with limited healthcare budgets. Manufacturers face the challenge of balancing innovation with affordability, as pediatric-specific R&D investments are substantial. To mitigate these barriers, strategies such as developing lower-cost alternatives, expanding insurance coverage, offering patient assistance programs, and implementing government subsidies are critical. Without such measures, the high expense of advanced devices and therapies will continue to impede adoption and limit the overall growth potential of the Global Pediatric Diabetes Management Market.

Key Market Trends

Integration of Digital Health Solutions

The integration of digital health solutions is a transformative trend in the Global Pediatric Diabetes Management Market, significantly enhancing the monitoring and management of pediatric diabetes. Digital health technologies, including mobile applications, cloud-based platforms, and telemedicine tools, allow caregivers and healthcare providers to access real-time data on blood glucose levels, insulin administration, and lifestyle factors. Continuous glucose monitoring (CGM) systems integrated with these platforms provide automated alerts for hypo- or hyperglycemic events, enabling timely interventions and reducing the risk of complications such as diabetic ketoacidosis. Integration of digital platforms with insulin pumps and automated insulin delivery (AID) systems further enhances personalized care by enabling real-time adjustments to insulin dosing based on predictive algorithms and trend analysis.

Remote monitoring capabilities offered by digital solutions allow healthcare professionals to supervise pediatric patients outside hospital settings, improving adherence and reducing the frequency of emergency visits or hospitalizations. These platforms also facilitate better communication between caregivers, patients, and clinicians, ensuring coordinated care and informed decision-making. Data collected through digital health systems can be analyzed to identify patterns in glucose fluctuations, evaluate the effectiveness of treatment protocols, and optimize long-term management strategies. Growing investment in healthcare IT infrastructure, increasing smartphone penetration, and rising awareness among parents and healthcare providers about the benefits of connected care are accelerating adoption of digital solutions. Integration of wearable sensors, artificial intelligence, and predictive analytics is enhancing the precision and efficiency of diabetes management, providing actionable insights and supporting proactive interventions. This convergence of technology and healthcare is shaping a patient-centric, data-driven approach, driving innovation and improving outcomes in pediatric diabetes management across diverse healthcare settings.

Key Market Players

• Medtronic plc
• DexCom, Inc.
• Abbott Laboratories
• Tandem Diabetes Care, Inc.
• Insulet Corporation
• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Roche Diabetes Care, Inc.
• Ascensia Diabetes Care Holdings AG

Report Scope:

In this report, the Global Pediatric Diabetes Management Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Diabetes Management Market, By Product:

• Blood Glucose Monitors (BGM)
• Continuous Glucose Monitors (CGM)
• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Pediatric Diabetes Management Market, By Technology:

• Connected Devices
• Non-connected Devices

Pediatric Diabetes Management Market, By End User:

• Hospitals
• Homecare
• Pediatric Clinics

Pediatric Diabetes Management Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Diabetes Management Market.

Available Customizations:

Global Pediatric Diabetes Management Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Pediatric Diabetes Management Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Blood Glucose Monitors (BGM), Continuous Glucose Monitors (CGM), Insulin Pumps, Insulin Pens, Insulin Syringes)
  • 5.2.2. By Technology (Connected Devices, Non-connected Devices)
  • 5.2.3. By End User (Hospitals, Homecare, Pediatric Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Pediatric Diabetes Management Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Diabetes Management Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Pediatric Diabetes Management Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Pediatric Diabetes Management Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End User

7. Europe Pediatric Diabetes Management Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pediatric Diabetes Management Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pediatric Diabetes Management Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pediatric Diabetes Management Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pediatric Diabetes Management Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pediatric Diabetes Management Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End User

8. Asia-Pacific Pediatric Diabetes Management Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pediatric Diabetes Management Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pediatric Diabetes Management Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Pediatric Diabetes Management Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Pediatric Diabetes Management Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pediatric Diabetes Management Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End User

9. South America Pediatric Diabetes Management Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Diabetes Management Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pediatric Diabetes Management Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pediatric Diabetes Management Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pediatric Diabetes Management Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Diabetes Management Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pediatric Diabetes Management Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pediatric Diabetes Management Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic plc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. DexCom, Inc.
• 15.3. Abbott Laboratories
• 15.4. Tandem Diabetes Care, Inc.
• 15.5. Insulet Corporation
• 15.6. Novo Nordisk A/S
• 15.7. Sanofi S.A.
• 15.8. Eli Lilly and Company
• 15.9. Roche Diabetes Care, Inc.
• 15.10. Ascensia Diabetes Care Holdings AG

16. Strategic Recommendations

17. About Us & Disclaimer